In:
ChemMedChem, Wiley, Vol. 2, No. 7 ( 2007-07-09), p. 1043-1053
Abstract:
A series of highly potent substrate‐analogue factor Xa inhibitors containing D ‐homophenylalanine analogues as the P3 residue has been identified by systematic optimization of a previously described inhibitor structure. An initial lead, benzylsulfonyl‐ d‐ hPhe‐Gly‐4‐amidinobenzylamide ( 3 ), inhibits fXa with an inhibition constant of 6.0 n M . Most modifications of the P2 amino acid and P4 benzylsulfonyl group did not improve the affinity and selectivity of the compounds as fXa inhibitors. In contrast, further variation at the P3 position led to inhibitors with significantly enhanced potency and selectivity. Inhibitor 27 , benzylsulfonyl‐ D ‐homo‐2‐pyridylalanyl(N‐oxide)‐Gly‐4‐amidinobenzylamide, inhibits fXa with a K i value of 0.32 n M . The inhibitor has strong anticoagulant activity in plasma and doubles the activated partial thromboplastin time and prothrombin time at concentrations of 280 n M and 170 n M , respectively. Compound 27 inhibits the prothrombinase complex with an IC 50 value of 5 n M and is approximately 50 times more potent than the reference inhibitor DX‐9065a in this assay.
Type of Medium:
Online Resource
ISSN:
1860-7179
,
1860-7187
DOI:
10.1002/cmdc.200700031
Language:
English
Publisher:
Wiley
Publication Date:
2007
detail.hit.zdb_id:
2209649-8
SSG:
15,3
Bookmarklink
